May 30, 2025: The Technology Development Board (TDB) under the Department of Science and Technology (DST) has approved funding for S3V Vascular Technologies Ltd, a Mysuru-based medical technology company, to support the development of India’s first indigenously made mechanical thrombectomy kits. These devices are used to treat acute ischemic strokes—a leading cause of disability and death, by removing blood clots quickly and effectively.
The project aims to set up a modern manufacturing unit at the Medical Devices Park in Sriperumbudur, near Chennai, where advanced stroke-care devices like stent retrievers, microcatheters, guidewires, and aspiration catheters will be made entirely in India. This innovation by SV3 Technology is expected to improve treatment results, reduce long-term disability, and significantly cut costs by replacing expensive imports with affordable, high-quality Indian alternatives.
“Mechanical thrombectomy can mean the difference between permanent paralysis and full recovery,” said TDB Secretary Rajesh Kumar Pathak, emphasizing the critical health benefits of the project.
TDB Backed S3V Vascular Technology: Key Benefits to Patients and the Indian Healthcare System
- Better Outcomes: Mechanical thrombectomy offers faster recovery and lower chances of permanent disability compared to traditional stroke treatments.
- Made in India: S3V will be the first Indian company to design and build these life-saving devices entirely within the country.
- Lower Costs: Local manufacturing will make treatment more affordable and accessible, especially for patients under government schemes like Ayushman Bharat.
- Global Reach: The company has started regulatory processes for CE and USFDA approvals, aiming to supply devices across India, Asia, Latin America, Europe, and the U.S.
- Training for Doctors: S3V also plans to train young doctors—especially in Tier-II cities—using simulators, helping improve stroke care across underserved areas.
S3V also plans to file patents for several of its core innovations, including a new clot retriever design and braid-over-coil catheter technology, solidifying its leadership in India’s MedTech space.
Speaking about the initiative, Dr. N.G. Vijaya Gopal, Managing Director of SV3, said, “This support allows us to reduce India’s dependency not just on imported devices, but also on raw materials. We’re building a full ecosystem for world-class, made-in-India stroke care.”
This project not only marks a major step in India’s healthcare innovation but also moves the country closer to becoming a global hub for affordable, high-end medical technology.
